Literature DB >> 25613332

Gadoxetic acid: pearls and pitfalls.

Ryan B Schwope1, Lauren A May, Michael J Reiter, Christopher J Lisanti, Daniel J A Margolis.   

Abstract

Gadoxetic acid is a hepatocyte-specific magnetic resonance imaging contrast agent with the ability to detect and characterize focal liver lesions and provide structural and functional information about the hepatobiliary system. Knowledge of the pharmacokinetics of gadoxetic acid is paramount to understanding imaging protocol and lesion appearance and facilitates identification and avoidance of undesired effects with use of this intravenous contrast agent. This article reviews the utility of gadoxetic acid in liver and biliary imaging, with emphasis on the hepatobiliary phase.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25613332     DOI: 10.1007/s00261-015-0354-7

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  4 in total

Review 1.  Focal liver lesions: Practical magnetic resonance imaging approach.

Authors:  António P Matos; Fernanda Velloni; Miguel Ramalho; Mamdoh AlObaidy; Aruna Rajapaksha; Richard C Semelka
Journal:  World J Hepatol       Date:  2015-08-08

2.  cDNA Microarray Analysis and Influx Transporter OATP1B1 in Liver Cells After Exposure to Gadoxetate Disodium, a Gadolinium-based Contrast Agent in MRI Liver Imaging.

Authors:  Chi-Cheng Lu; Wen-Kang Chen; Jo-Hua Chiang; Yuh-Feng Tsai; Yu-Ning Juan; Ping-Chin Lin; Yeu-Sheng Tyan; Jai-Sing Yang
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

3.  Convolutional neural network-automated hepatobiliary phase adequacy evaluation may optimize examination time.

Authors:  Guilherme Moura Cunha; Kyle A Hasenstab; Atsushi Higaki; Kang Wang; Timo Delgado; Ryan L Brunsing; Alexandra Schlein; Armin Schwartzman; Albert Hsiao; Claude B Sirlin; Katie J Fowler
Journal:  Eur J Radiol       Date:  2020-01-14       Impact factor: 3.528

4.  Quantitative evaluation of Gd-EOB-DTPA uptake in focal liver lesions by using T1 mapping: differences between hepatocellular carcinoma, hepatic focal nodular hyperplasia and cavernous hemangioma.

Authors:  Zhenpeng Peng; Chang Li; Tao Chan; Huasong Cai; Yanji Luo; Zhi Dong; Zi-Ping Li; Shi-Ting Feng
Journal:  Oncotarget       Date:  2017-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.